|Bid||0.4010 x 3000|
|Ask||0.4080 x 29200|
|Day's range||0.3600 - 0.3994|
|52-week range||0.3400 - 7.0700|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Earnings date||08 Aug 2022 - 12 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.33|
Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.
Endo International (NASDAQ: ENDP), a specialty pharmaceutical company, saw its shares fall 69% on Wednesday. It was already a bad day for many companies with the Dow and the S&P 500 down more than 3% and the NASDAQ falling more than 4%. The biggest reason for Endo's massive drop came when The Wall Street Journal reported the company was negotiating to restructure its more-than $8 billion in debt with its lenders and senior bondholders.
Endo (ENDP) tops Q1 earnings and sales estimates. However, Vasostrict faces generic competition and the guidance for Q2 is dismal.